Since the dawn of kidney transplantation, doctors have used a “genetic footprint” called human leukocyte antigens, or HLA, to evaluate the strength of the match between donor and recipient.

Now, researchers at the University of Pittsburgh have found another marker that also has a strong association with the clinical outcomes of a kidney transplant. Their findings were published earlier this month in Science Translational Medicine.

“A very simple blood test allows us to risk-stratify patients that are at risk for poor outcomes,” said Aravind Cherukuri, senior author of the study and co-director of clinical research at Pitt’s Thomas E. Starzl Transplantation Institute.

The blood test can show the variant of a surface receptor called SIRP-alpha on innate immune cells known as monocytes. A Pitt study in 2017 found that in mice, SIRP-alpha is involved in helping the immune system distinguish whether something is a foreign body, and whether to mount an immune response.

Advertise with us

This study tested the role of SIRP-alpha in transplantation first in mice, establishing that kidneys transplanted in mice with the same SIRP-alpha variants looked healthier than those with mismatched SIRP-alpha types.

Then, the researchers started to gather data on humans who had had kidney transplants. They were able to find 455 donor-recipient pairs who had received kidney transplants at UPMC between 2013 and 2019 and analyzed their blood samples to see which ones had SIRP-alpha matches or mismatches. They found that when the SIRP-alpha types did not match, the kidney recipients were more likely to have early acute graft rejection, scarring and worse long-term outcomes.

Researchers looked at delayed acute rejection, which is acute rejection that occurs five to 12 months after transplant, because it is associated with increased risk of graft loss, when the kidney doesn’t function properly after transplantation.

They found that patients with a SIRP-alpha mismatch had two to three times higher rates of delayed acute organ rejection compared to matched patients.

They were able to validate their findings again in a different group of patients that had participated in kidney transplants at Northwestern University.

Advertise with us

“Again, in their cohort, if there was a mismatch, there was a strong trend toward worse outcomes,” said Cherukuri, who is also a nephrologist at UPMC and an assistant professor of medicine, surgery and immunology at Pitt.

The discovery does not mean that SIRP-alpha matching should be used in place of HLA matching in kidney transplants, said Cherukuri, noting that HLA is still the genetic fingerprint of the transplant.

And while HLA and SIRP-alpha matches would be ideal in kidney transplants, neither is required.

Kidney transplants are done frequently even when there is an HLA mismatch, he said, because those transplants still result in better outcomes than long-term dialysis, which is the alternative to a kidney transplant for many patients.

In theory, SIRP-alpha matches could be used to choose the best option between multiple kidneys, but, in reality, most kidney transplant recipients do not have multiple organs available to them.

Advertise with us

Practically, the data on SIRP-alpha matches would most likely be used to evaluate whether a more or less aggressive regimen of immunosuppressant drugs should be employed to prevent rejection. When organs are transplanted between identical twins, they don’t need immunosuppression because their genetic makeup is so similar, said Cherukuri.

Similarly, dosages or types of immunosuppressants could be tailored to all organ recipients depending on the HLA and SIRP-alpha match or mismatch. Half of patients with transplants don’t use corticosteroids to prevent rejection because of side effects, he said, so more information on their rejection risk could help the decision on which patients should use the drugs despite side effects, and which patients could discontinue use.

It’s a potential clinical change that has evolved from Pitt’s basic science discovery in 2017 of the role of SIRP-alpha in recognizing self from non-self. Fadi Lakkis, who did that research at Pitt and is now a professor at Stanford, was also an author on the current study. That discovery in 2017 upended the previous understanding of what drives the response in innate immune cells.

“It’s a massive paradigm shift in our understanding of how innate cells are activated in the context of transplantation and how that is related to clinical outcomes,” said Cherukuri. “This entire thing flowed seamlessly from mouse biology to humans.”

That basic science will hopefully lead to clinical outcomes where there is less rejection and failure of transplanted organs, and patients can keep their transplanted organs for the rest of their lives — meaning better outcomes for patients and more organs available for transplant. 

“That’s the dream for everybody,” said Cherukuri. “What we believe is that this is one step toward that.”